Beigene Ltd
SSE:688235

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
SSE:688235
Watchlist
Price: 166.43 CNY 0.02% Market Closed
Market Cap: 226.1B CNY
Have any thoughts about
Beigene Ltd?
Write Note

Operating Margin
Beigene Ltd

-30.4%
Current
-117%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-30.4%
=
Operating Profit
-6.7B
/
Revenue
22.2B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
KY
Beigene Ltd
SSE:688235
229.5B CNY
-30%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
28%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
133.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-22%
Country KY
Market Cap 229.5B CNY
Operating Margin
-30%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 312.7B USD
Operating Margin
28%
Country US
Market Cap 158.3B USD
Operating Margin
19%
Country US
Market Cap 115.9B USD
Operating Margin
40%
Country US
Market Cap 112.4B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.6B AUD
Operating Margin
26%
Country US
Market Cap 82.6B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.5B EUR
Operating Margin
-22%
No Stocks Found

Beigene Ltd
Glance View

Market Cap
229.5B CNY
Industry
Biotechnology

Beigene Ltd., a globally recognized biotechnology company, has emerged as a significant player in the fight against cancer through its innovative treatments and robust pipeline of therapies. Founded in 2010, the company has its roots in China and quickly expanded its presence within the international oncology market, focusing on the discovery, development, and commercialization of medicines to treat cancer. Beigene is particularly known for its groundbreaking drug, Brukinsa (zanubrutinib), which targets specific malignancies and has garnered approval across various jurisdictions, including the U.S. and China. This strategic focus on precision medicine not only positions Beigene at the forefront of cancer treatment advancements but also highlights its commitment to addressing unmet medical needs. Investors looking at Beigene Ltd. can appreciate its aggressive growth trajectory and strategic collaborations with leading pharmaceutical companies, which enhance its R&D capabilities and market reach. The company’s upcoming product launches and ongoing clinical trials present considerable opportunities for revenue generation. Additionally, with a strong balance sheet and a vision to alleviate the global cancer burden, Beigene is not just advancing science; it's actively contributing to the well-being of patients worldwide. As the global healthcare landscape evolves, Beigene's innovation-driven approach and commitment to quality position it as a promising investment in the ever-expanding biopharmaceutical sector.

Intrinsic Value
157.64 CNY
Overvaluation 5%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-30.4%
=
Operating Profit
-6.7B
/
Revenue
22.2B
What is the Operating Margin of Beigene Ltd?

Based on Beigene Ltd's most recent financial statements, the company has Operating Margin of -30.4%.